Since the approval of the first biosimilar in Europe more than a decade ago, the use of biosimilars has been increasing there. Biosimilars have been gaining traction in the United States as well following the FDA's approval of the first biosimilar in 2015. For biosimilars to achieve and maintain a strong position in the major pharmaceutical markets, they must earn physicians' trust. By elucidating physicians’ decision-making process in the use of biosimilars versus biologics, clients can learn the most important attributes that a biosimilar should have. Decision Resources Group conducted primary market research in the United States, France, and Germany with physicians from six specialties to obtain insight into their experiences with and perceptions of biosimilars. In this report, we examine how physicians’ experiences and attitudes compare across specialties and countries and how their views have evolved over time.

Questions Answered in This Report:

  • Understand surveyed physicians’ stance on indication extrapolation and automatic substitution. What are physicians’ opinions of indication extrapolation, and how do their attitudes vary by country and specialty? Are physicians familiar with the pharmacy-level substitution rules in their respective countries, and are they receptive to them?
  • Understand the drivers of and barriers to biosimilar use among physicians from different specialties. According to physicians, which factors will stimulate uptake of biosimilars, and how do these factors vary by country? What are physicians’ concerns about using biosimilars, and how do they vary by specialty? Which companies do physicians trust most as manufacturers of biosimilars?
  • Understand how examining physicians’ attitudes can help decipher the likely use of biosimilars in the future. How will physicians adopt biosimilars initially, and how will uptake vary by specialty? How will physicians choose among multiple biosimilars of the same reference product? Do physicians expect to use new, higher-cost biologics once biosimilars are available?

Scope

Markets covered: United States, France, and Germany.

Primary research: Online quantitative survey of 547 physicians from six specialties—endocrinologists, gastroenterologists, nephrologists, rheumatologists, hematologist-oncologists, and medical oncologists.

Table of contents

  • Biosimilars - Current Treatment - Biosimilars | Current Treatment | Landscape | US/EU
    • Current Treatment: Biosimilars Landscape Report 2020

Author(s): John Crowley

John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a Ph.D. from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.